

Press Release

BSE: 506690

NSE: UNICHEMLAB

Reuters: UNLB.BO

Bloomberg: UL:IN

Mumbai, Thursday January 23, 2014

Unichem Laboratories receives ANDA approval from USFDA for METRONIDAZOLE TABLETS

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (U.S. FDA) for Metronidazole *USP Tablets*.

Metronidazole USP Tablets 250mg and 500mg are therapeutically equivalent to Flagyl Tablets 250mg and 500mg of *G.D Searle LLC*.

Metronidazole Tablet USP is an anti-infective agent used to treat a variety of bacterial and protozoal infections.

The product will be commercialized from Unichem's Ghaziabad plant. Active pharmaceutical ingredient i.e., Metronidazole used for this ANDA is also made in house at Roha plant.

Currently, around 6 other companies have generic approvals for the US market and the estimated market size is over US\$ 100 Million.

About Unichem Laboratories Limited.

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms. More information about the company can be found at www.unichemlabs.com.

For more information please contact:

Mr.M Gundu Rao / Mr. K Subharaman

Ph: +91-22-66888 380

Ph: +91-22-66888 404

E-mail: gundurao@unichemlabs.com

subharamank@unichemlabs.com

Mr. Rakesh Parikh/ Mr. Monish Shah

Ph: +91-22-66888 414

Ph: +91-22-66888 509

E-mail: rparikh@unichemlabs.com

monish.shah@unichemlabs.com

Disclaimer: This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.